Putnam Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $2.93M | Buy |
23,838
+1,756
| +8% | +$219K | ﹤0.01% | 673 |
|
|
2023
Q3 | $2.86M | Buy |
+22,082
| New | +$2.94M | ﹤0.01% | 633 |
|
|
2021
Q2 | – | Sell |
-12,846
| Closed | -$2.11M | – | 815 |
|
|
2021
Q1 | $2.11M | Sell |
12,846
-59,855
| -82% | -$9.85M | ﹤0.01% | 670 |
|
|
2020
Q4 | $12M | Sell |
72,701
-201,997
| -74% | -$30.1M | 0.02% | 341 |
|
|
2020
Q3 | $39.2M | Sell |
274,698
-383,680
| -58% | -$47.6M | 0.08% | 173 |
|
|
2020
Q2 | $72.6M | Sell |
658,378
-19,436
| -3% | -$2.15M | 0.15% | 120 |
|
|
2020
Q1 | $67.6M | Sell |
677,814
-49,129
| -7% | -$6.35M | 0.18% | 122 |
|
|
2019
Q4 | $109M | Sell |
726,943
-451,029
| -38% | -$61.4M | 0.22% | 118 |
|
|
2019
Q3 | $151M | Sell |
1,177,972
-50,403
| -4% | -$6.76M | 0.34% | 90 |
|
|
2019
Q2 | $175M | Sell |
1,228,375
-53,644
| -4% | -$7.21M | 0.39% | 79 |
|
|
2019
Q1 | $183M | Sell |
1,282,019
-1,797,005
| -58% | -$234M | 0.43% | 75 |
|
|
2018
Q4 | $382M | Sell |
3,079,024
-1,239,724
| -29% | -$184M | 1.01% | 17 |
|
|
2018
Q3 | $726M | Sell |
4,318,748
-591,613
| -12% | -$102M | 1.57% | 7 |
|
|
2018
Q2 | $846M | Sell |
4,910,361
-2,271,515
| -32% | -$371M | 1.93% | 4 |
|
|
2018
Q1 | $1.08B | Sell |
7,181,876
-1,090,696
| -13% | -$160M | 2.52% | 2 |
|
|
2017
Q4 | $1.11B | Sell |
8,272,572
-9,222
| -0.1% | -$1.28M | 2.48% | 2 |
|
|
2017
Q3 | $1.21B | Sell |
8,281,794
-22,316
| -0.3% | -$3.37M | 2.8% | 2 |
|
|
2017
Q2 | $1.29B | Buy |
8,304,110
+457,598
| +6% | +$70M | 3.02% | 1 |
|
|
2017
Q1 | $1.14B | Buy |
7,846,512
+178,426
| +2% | +$23.2M | 2.67% | 2 |
|
|
2016
Q4 | $836M | Buy |
7,668,086
+103,648
| +1% | +$11.5M | 2.02% | 4 |
|
|
2016
Q3 | $919M | Sell |
7,564,438
-480,120
| -6% | -$64.7M | 2.21% | 2 |
|
|
2016
Q2 | $1.14B | Sell |
8,044,558
-2,278,848
| -22% | -$336M | 2.77% | 2 |
|
|
2016
Q1 | $1.35B | Sell |
10,323,406
-39,692
| -0.4% | -$4.94M | 3.2% | 2 |
|
|
2015
Q4 | $1.46B | Buy |
10,363,098
+290,600
| +3% | +$40.3M | 3.29% | 2 |
|
|
2015
Q3 | $1.34B | Buy |
10,072,498
+1,663,972
| +20% | +$287M | 2.99% | 2 |
|
|
2015
Q2 | $1.48B | Buy |
8,408,526
+272,851
| +3% | +$49M | 2.97% | 2 |
|
|
2015
Q1 | $1.41B | Buy |
8,135,675
+343,471
| +4% | +$58.9M | 2.8% | 2 |
|
|
2014
Q4 | $1.28B | Sell |
7,792,204
-81,279
| -1% | -$13.5M | 2.62% | 2 |
|
|
2014
Q3 | $1.26B | Buy |
7,873,483
+225,744
| +3% | +$34.7M | 2.68% | 2 |
|
|
2014
Q2 | $1.12B | Buy |
7,647,739
+1,545,526
| +25% | +$214M | 2.42% | 2 |
|
|
2014
Q1 | $846M | Buy |
6,102,213
+741,611
| +14% | +$112M | 1.91% | 3 |
|
|
2013
Q4 | $678M | Buy |
5,360,602
+2,336,944
| +77% | +$242M | 1.63% | 4 |
|
|
2013
Q3 | $278M | Sell |
3,023,658
-595,745
| -16% | -$48.1M | 0.74% | 23 |
|
|
2013
Q2 | $249M | Buy |
+3,619,403
| New | +$221M | 0.73% | 24 |
|
Other funds holding JAZZ
PCM
Putnam Investments's JAZZ Position: Q4 2023 in Review
Putnam Investments increased its Jazz Pharmaceuticals (JAZZ) stake by 8% in Q4 2023, buying an estimated $219K and bringing the position to 23,838 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #673.
Putnam Investments first reported a position in JAZZ in Q2 2013 and has held it in 34 quarters since. The position peaked at $1.48B in Q2 2015. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.
- Putnam Investments held 23,838 shares of Jazz Pharmaceuticals worth $2.93M as of Q4 2023.
- Putnam Investments bought 1,756 Jazz Pharmaceuticals shares in Q4 2023, an estimated $219K.
- Jazz Pharmaceuticals made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #673 holding.
- Putnam Investments first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- Putnam Investments's Jazz Pharmaceuticals position peaked at $1.48B in Q2 2015.
- 499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.
Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.